Ocaliva (obeticholic acid) – New contraindication for the treatment of primary biliary cholangitis (PBC)
09/06/2022
Medicines for human use
Direct healthcare professional communication (DHPC)
Ocaliva (obeticholic acid): New contraindication for the treatment of primary biliary cholangitis (PBC) in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation